Illumina CEO 'Optimistic' about Array Business as Q1 Sales Spike 47 Percent
May 03, 2011
Illumina CEO 'Optimistic' about Array Business as Q1 Sales Spike 47 Percent
The "continued success" of its next-generation sequencing instruments and "strong results" in its array business helped the company report a 47-percent increase in first-quarter sales.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Illumina CEO Discusses ENCODE, GWAS, and NIH Funding at Investor Conference
September 18, 2012 / BioArray News - Illumina's Q2 Sales Rise 36 Percent on Sequencing Demand, 'Overall Improvement' in Array Sales
August 2, 2011 / BioArray News - Q&A: NCI's Stephen Chanock on the Three Waves of Genome-Wide Association Studies
March 1, 2011 / BioArray News - Illumina CEO: Array Market Returned to 'Normalcy' in 2010 as BeadChip Sales Rose 10 Percent
January 18, 2011 / BioArray News - Will Population-Specific Chips Power the Next Round of GWAS?
November 9, 2010 / BioArray News